Entrada Therapeutics, Inc. (NASDAQ:TRDA) CFO Kory James Wentworth Sells 1,758 Shares of Stock

Entrada Therapeutics, Inc. (NASDAQ:TRDA) CFO Kory James Wentworth sold 1,758 shares of Entrada Therapeutics stock in a transaction that occurred on Monday, July 8th. The stock was sold at an average price of $14.95, for a total value of $26,282.10. Following the completion of the transaction, the chief financial officer now owns 81,412 shares of the company’s stock, valued at approximately $1,217,109.40. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website.

Entrada Therapeutics Trading Up 1.2 %

Shares of NASDAQ:TRDA opened at $15.74 on Thursday. Entrada Therapeutics, Inc. has a 12 month low of $10.75 and a 12 month high of $18.44. The company has a market capitalization of $531.38 million, a price-to-earnings ratio of 24.98 and a beta of -0.25. The firm’s 50-day moving average is $14.91 and its 200 day moving average is $14.31.

Entrada Therapeutics (NASDAQ:TRDA) last released its earnings results on Tuesday, May 7th. The company reported $0.68 EPS for the quarter, beating analysts’ consensus estimates of ($0.38) by $1.06. Entrada Therapeutics had a return on equity of 9.73% and a net margin of 14.42%. The firm had revenue of $59.12 million for the quarter, compared to analysts’ expectations of $25.00 million. As a group, equities analysts forecast that Entrada Therapeutics, Inc. will post -0.13 EPS for the current fiscal year.

Institutional Trading of Entrada Therapeutics

A number of hedge funds and other institutional investors have recently bought and sold shares of TRDA. Vanguard Group Inc. boosted its stake in shares of Entrada Therapeutics by 1.3% during the first quarter. Vanguard Group Inc. now owns 1,078,908 shares of the company’s stock valued at $15,288,000 after purchasing an additional 13,742 shares during the period. Wellington Management Group LLP boosted its position in Entrada Therapeutics by 2.6% in the 3rd quarter. Wellington Management Group LLP now owns 1,045,652 shares of the company’s stock valued at $16,521,000 after buying an additional 26,144 shares during the period. Strs Ohio boosted its position in Entrada Therapeutics by 792.6% in the 4th quarter. Strs Ohio now owns 24,100 shares of the company’s stock valued at $363,000 after buying an additional 21,400 shares during the period. Allspring Global Investments Holdings LLC grew its stake in Entrada Therapeutics by 427.6% in the 1st quarter. Allspring Global Investments Holdings LLC now owns 14,763 shares of the company’s stock worth $209,000 after acquiring an additional 11,965 shares in the last quarter. Finally, SG Americas Securities LLC increased its position in shares of Entrada Therapeutics by 27.7% during the fourth quarter. SG Americas Securities LLC now owns 11,714 shares of the company’s stock worth $177,000 after acquiring an additional 2,540 shares during the period. Hedge funds and other institutional investors own 86.39% of the company’s stock.

Analyst Ratings Changes

Separately, HC Wainwright dropped their price objective on shares of Entrada Therapeutics from $20.00 to $18.00 and set a “buy” rating for the company in a research note on Tuesday, June 25th.

Entrada Therapeutics Company Profile

Entrada Therapeutics, Inc, a clinical-stage biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its EEV platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. Its therapeutic candidates, which include ENTR-601-44, which is in Phase I clinical trial for the treatment of Duchenne muscular dystrophy; and ENTR-701, which is in Phase 1/2 clinical trial for the treatment of myotonic dystrophy type 1.